Investor Event Attendance and Presentation

RNS Number : 9688K

Open Orphan PLC

03 September 2019

 

03 September 2019

Open Orphan Plc

("Open Orphan" or the "Company")

Investor Event Attendance and Presentation

Open Orphan presents at Shares Investor Evening, London

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at the Shares Investor Evening tomorrow from 18:00 at Novotel Hotel Tower Bridge, London, EC3N 2NR.

Cathal Friel, Open Orphan's Chief Executive Officer will be presenting from 18:30 onwards to update existing and potential investors on the Company's business plans for 2019-2020.

The event will provide an opportunity for investors to hear about the progress being made by the Company following the reverse takeover of Venn Life Sciences and the potential for Open Orphan moving forward.

A link to the presentation will be made available on the Company website following the event.

For further information on the Shares Investor Evening, please visit the event website https://www.sharesmagazine.co.uk/events/event/shares-investor-evening-london-040919 

Enquiries:

Open Orphan Plc Tel: [phone]
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: [phone]
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: [phone]
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: [phone]
Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

 

END

 

 

NRAUGUUABUPBGQP